LUNGevity Foundation· @LUNGevity · X·· 2026-04-19Score60
Reading
Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T
局部 nivolumab · Oral pre-cancer clinical response 85%, 1-year clearance 82%
Body
Dr. Tina Cascone
@UTMDAnderson
shared a subgroup analysis from the phase 3 CheckMate77T study of perioperative nivolumab in resectable #NSCLC. Genomic markers and ctDNA levels may have a role in predicting outcomes and guiding treatment but require follow up studies. #AACR26
Heat 2 · 1 like · 0 replies · 1 repost
Conference abstracts
Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay
Read the abstract →Source: LUNGevity Foundation · x.com